Kiniksa Pharmaceuticals International, plc Total Liabilities
Kiniksa Pharmaceuticals International, plc (KNSA) had Total Liabilities of $219.59 million as of 2026-03-31, per its 10-Q filed 2026-04-28.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-04-28
- 2026-03-31: Liabilities $219.59M.
- 2025-12-31: Liabilities $196.03M.
- 2025-09-30: Liabilities $176.95M.
- 2025-06-30: Liabilities $166.14M.
| Period end | Liabilities |
|---|---|
| 2026-03-31 | $219.59M 10-Q · filed 2026-04-28 |
| 2025-12-31 | $196.03M 10-Q · filed 2026-04-28 |
| 2025-09-30 | $176.95M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $166.14M 10-Q · filed 2025-07-29 |
| 2025-03-31 | $141.84M 10-Q · filed 2025-04-29 |
| 2024-12-31 | $142.12M 10-K · filed 2026-02-24 |
| 2024-09-30 | $118.29M 10-Q · filed 2024-10-29 |
| 2024-06-30 | $107.33M 10-Q · filed 2024-07-25 |
| 2024-03-31 | $87.78M 10-Q · filed 2024-04-25 |
| 2023-12-31 | $87.48M 10-K · filed 2025-02-25 |
| 2023-09-30 | $77.94M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $72.68M 10-Q · filed 2023-08-01 |
| 2023-03-31 | $52.77M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $63.52M 10-K · filed 2024-02-28 |
| 2022-09-30 | $75.94M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $57.08M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $64.72M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $47.76M 10-K · filed 2023-03-02 |
| 2021-09-30 | $38.81M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $43.42M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $40.46M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $37.53M 10-K · filed 2022-02-24 |
| 2020-09-30 | $25.90M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $21.02M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $20.27M 10-Q · filed 2020-05-04 |
| 2019-12-31 | $29.11M 10-K · filed 2021-02-25 |
| 2019-09-30 | $29.89M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $32.94M 10-Q · filed 2019-08-13 |
| 2019-03-31 | $39.64M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $42.70M 10-K · filed 2020-03-05 |
| 2018-09-30 | $28.19M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $23.33M 10-Q · filed 2018-08-06 |
| 2017-12-31 | $17.43M 10-K · filed 2019-03-12 |